Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2016 Archives
Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Supplemental New Drug Application (sNDA) for Morphine Sulfate... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 a.m.... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) granted the company a 90-day extension to submit documentation concerning its Methylphenidate... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Metaxalone Tablets... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Memantine... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Jefferies London Healthcare Conference on November 16, 2016 at 2:40 p.m. (GMT) at the Waldorf Hilton hotel in... More |
--Net Sales Increased 52% to Approximately $162 Million; Company Revises Guidance for Fiscal 2017-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 first quarter ended September 30, 2016. The company completed the acquisition of Kremers Urban... More |
Lannett Company, Inc. (NYSE: LCI) today announced successful results from a placebo-controlled Phase III clinical study evaluating C-Topical® (cocaine hydrochloride solution) 4% and 10% as a... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2017 first quarter on Thursday, November 3, 2016, after the market closes. Lannett management... More |
Lannett Company, Inc. (NYSE: LCI) received a notice from the U.S. Food and Drug Administration (FDA) that it will seek to withdraw approval of the Company's Abbreviated New Drug Application (ANDA)... More |
Lannett Company, Inc. (NYSE: LCI) today announced the resignation of its chief of scientific affairs, Mahendra Dedhiya, Ph.D., effective October 21, 2016. "Mahendra joined Lannett last year as... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Buprenorphine and... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) recently completed a cGMP inspection of the company's manufacturing facility in Philadelphia, as... More |
--Company Reports Fourth Quarter Net Sales Increased 70% to Approximately $169 Million, GAAP Diluted EPS of $0.10, Adjusted Diluted EPS of $0.73; Provides Guidance for Fiscal 2017-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 fourth quarter and full year ended June 30, 2016. As previously announced, the company completed the... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2016 fourth quarter and full year on Tuesday, August 23, 2016, after the market closes.... More |
--Company Appoints Kristie Stephens Vice President Regulatory Affairs and Chief Compliance Officer and John Kozlowski Vice President Financial Operations and Corporate Controller-- Lannett Company, Inc. (NYSE: LCI) today announced two promotions. Kristie Stephens has been appointed vice president of regulatory affairs and chief compliance officer, and John Kozlowski has been... More |
Lannett Company, Inc. (NYSE: LCI) today announced that its strategic partner, Sparsha Pharma USA, Inc., has received an Acceptable for Filing letter from the U.S. Food and Drug Administration... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it recently received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Paroxetine... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Diazepam Oral... More |
--Overcomes Volatile Market to Achieve Significant Interest Savings-- Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the repurchase of the remaining $200 million of the 12% Senior Notes due in 2023, after successfully amending its existing... More |
--Company Previously Completed the Repurchase of $50 Million of 12% Senior Notes-- Lannett Company, Inc. (NYSE: LCI) today announced that it has reached an agreement with an existing lender to raise an incremental $150 million Term Loan B, and is also seeking to amend certain... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Neomycin Sulfate... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the repurchase of $50 million of the $250 million aggregate principal amount of the 12% Senior Notes due in 2023 in open... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it expects to repurchase $50 million of the $250 million aggregate principal amount of the 12% Senior Notes due in 2023 in open market... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016 at 3:40 p.m. PT at the Encore at... More |
| 1-25 26-40 |